Loading patent…
AssigneesInger Sandlie, Bjarne Bogen, Sibjorn Fossum
InventorsBjarne Bogen, Inger Sandlie, Sigbjørn Fossum, Siri Mjaaland, Elin Lunde, Ingunn B. Rasmussen
Estimating the term…
A modified immunoglobulin (Ig) molecule incorporates, preferably in one or more non-CDR loops, one or more foreign antigenic peptides such as a ras peptide. The antigen binding site of the immunoglobulin preferably recognises dendritic antigen presenting cells (APCs). The modified Ig can thus be taken up by dendritic APCs and the foreign antigenic peptide presented on MHC II to naive T-helper cells which stimulate cytotoxic T-cells via the production inter alia of IL-2. Modified Igs of the invention can be used to stimulate the immune system which has apparently become tolerant of a mutant protein, e.g., in the case of certain types of cancer, or it could be used for vaccination against viral infections. The modified Ig can be expressed from recombinant host cells from which it is secreted, notwithstanding the presence of the foreign pepide in a loop of the molecule.
A modified immunoglobulin molecule or functional fragment or part thereof (herein referred to as a modified Ig), having an antigenic peptide foreign to the Ig incorporated in one or more non-CDR loops, and wherein the main outline of the constant domain framework is maintained.
A modified immunoglobulin or functional fragment or part thereof (herein referred to as a modified Ig), having a foreign antigenic peptide that is foreign to the Ig incorporated in the Ig structure at a position corresponding to a loop of the Ig other than the Ig's CDR loops, and a recognition site for dendritic antigen-presenting cells (herein referred to as dendritic APCs), and wherein the main outline of the constant domain framework is maintained.
Dependencies are inferred from the claim text.